Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)
NCT ID: NCT00616993
Last Updated: 2011-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
120 participants
INTERVENTIONAL
2008-01-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
NCT00429923
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
NCT00430092
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)
NCT00616070
Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
NCT00406341
Study of Difluprednate in the Treatment of Uveitis
NCT00501579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Vehicle
Placebo
Vehicle
1
Difluprednate
Difluprednate
Difluprednate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Difluprednate
Difluprednate
Placebo
Vehicle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sirion Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sirion Therapeutics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roger Vogel, MD
Role: STUDY_CHAIR
Sirion Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eye Associates of Fort Myers
Fort Myers, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ST-601-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.